Cyclophosphamide for CLL: to be or not CYP2B activated?-Reference-Cited by-同舟云学术

Cyclophosphamide for CLL: to be or not CYP2B activated?

Published:2013-12-19 Issue:26 Volume:122 Page:4156-4157
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Geisler Christian H.¹

Affiliation:

1. RIGSHOSPITALET

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/26/4156/1372262/4156.pdf

Reference8 articles.

1. CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia.;Johnson;Blood,2013

2. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.;Yamauchi;Clin Cancer Res,2001

3. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.;Catovsky;Lancet,2007

4. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.;Eichhorst;Blood,2006

5. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.;Flinn;J Clin Oncol,2007

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Digestive properties and effects of Chimonanthus nitens Oliv polysaccharides on antioxidant effects in vitro and in immunocompromised mice;International Journal of Biological Macromolecules;2021-08

2. Drug Metabolism;Pharmacognosy;2017